eLife assessment
This study presents valuable findings on the risk factors of avascular osteonecrosis in patients with Gaucher disease. The evidence supporting the claims of the authors is convincing. The work will interest clinicians who treat patients with inborn errors of metabolism.
Reviewer #1 (Public Review):
This study presents a valuable finding for the incidence of bone avascular necrosis (AVN) in patients with Gaucher's Disease (GD) for twenty years. Furthermore, the evidence supporting the claims of the authors is solid.
The study's significant limitations relate to small numbers of patients, with only 155 GD patients analyzed. While the study period is excellent for incidence detection at 20 years, the overall number limits the strength of the analysis for cofactors. For example, there is an analysis for linkage to the type of therapy, the GBA1 genotype, spleen status, biomarkers, and other disease indicators. However, substantial numbers that would dictate changes to a preferential enzyme are not convincing. Moreover, the authors described 16 episodes of AVN in 14 patients, again making generalization difficult. Finally, there was a focus on Serum GlcSph levels, and the authors attempted to correlate levels according to probabilities for AVN occurrence while on treatment.
Overall, however, this is one of the best longitudinal studies for the incidence of AVN in GD patients, and the work will be of interest to medical biologists and professionals treating GD patients.
Reviewer #2 (Public Review):
Gaucher disease is a rare genetic disorder that is commonly treated by either administration of a functional enzyme or reduction of the substrate. Some patients receiving enzyme replacement therapy develop avascular osteonecrosis (AVN), but the risk factors were not known. In this study, a cohort of 155 patients was followed longitudinally for two decades, and their risk of developing AVN was analyzed. The data convincingly shows that patients with heterozygous N409S mutation, a past history of AVN, receiving velaglucerase therapy, or with higher serum glucosylsphingosine levels have a higher risk of AVN. These findings will provide a means to identify Gaucher disease patients at higher risk of AVN and to provide them with an optimal treatment. In addition, the study establishes that it is prudent to achieve a low glucoylspingosine level as a therapeutic goal in Gaucher patients with risk of AVN.
